Back to Results
First PageMeta Content
Pharmaceutical sciences / Pharmacology / Micafungin / False Claims Act / Astellas Pharma / Qui tam / Food and Drug Administration / Law / Antifungals / Echinocandins


MODEL PRESS RELEASE Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Relating to Marketing of Drug Mycamine The National Association of Medicaid Fraud Control Units announced on July 11,
Add to Reading List

Document Date: 2014-07-11 12:42:09

Open Document

File Size: 50,85 KB

Share Result on Facebook

City

Northbrook / /

Company

Astellas Pharma US Inc. / /

Currency

USD / /

Facility

United States District Court / /

IndustryTerm

pharmaceutical drugs / /

MedicalCondition

serious and invasive infections / infections / Candida infections / /

Organization

FDA / United States District Court for the Easter District of Pennsylvania / federal government / National Association of Medicaid Fraud Control Units / /

Position

Attorneys General / /

Product

Mycamine / /

ProvinceOrState

Texas / South Carolina / Illinois / California / New York / District of Columbia / Pennsylvania / /

SocialTag